Mental Health, Psychological Features and Psychiatric Comorbidity of Adolescents with Atopic Dermatitis: A Review
Lugović-Mihić L, Bukal D, Dolački L, Zanze L, Barac E, Tomašević R and Vilibić M
Mental Health, Psychological Features and Psychiatric Comorbidity of Adolescents with Atopic Dermatitis: A Review
Lugović-Mihić L, Bukal D, Dolački L, Zanze L, Barac E, Tomašević R and Vilibić M
Adolescence is a sensitive period of development marked by significant changes. The quality of life (QoL) of adolescents with atopic dermatitis (AD) can be substantially impacted by the disease. The chronic nature of AD is particularly significant: due to recurring (relapsing) skin lesions, adolescents are likely exposed to greater stress and depressive symptoms than those experiencing transient or one-time symptoms. Aesthetic and functional AD skin lesions during adolescence lead to reduced happiness, high stress and depression.
A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox) for the Treatment of Hemifacial Spasm
Kongsaengdao S, Arayawichanont A, Samintharapanya K, Rojanapitayakorn P, Maneeton B and Maneeton N
A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox) for the Treatment of Hemifacial Spasm
Kongsaengdao S, Arayawichanont A, Samintharapanya K, Rojanapitayakorn P, Maneeton B and Maneeton N
Previous randomized controlled trials (RCTs) investigating Botulinum toxin A (BoNT-A) for treatment of hemifacial spasm (HFS) have primarily focused on symptom relief and quality-of-life improvement. However, head-to-head comparisons of different BoNT-A formulations, particularly in terms of onset, duration of action, and efficacy, remain limited. We conducted a 12-week prospective, randomized controlled trial comparing the efficacy and safety of 33.33 units of Neubotulinum toxin A (Neu-BoNT-A) with 100 units of Abobotulinum toxin A (Abo-BoNT-A) in the treatment of HFS. A total of 87 patients were enrolled between September and December 2024. Neu-BoNT-A and Abo-BoNT-A exhibited similar onset and duration of action [5.0 ± 0.9 vs. 6.2 ± 0.7 days, respectively ( = 0.33)]. After 12 weeks of treatment, Neu-BoNT-A demonstrated superior efficacy in reducing the daily duration of HFS (2.00 ± 0.06 vs. 1.42 ± 0.10 h/day, < 0.001) and improving sleep duration (1.37 ± 0.01 vs. 1.06 ± 0.01 h/day, < 0.001). However, Abo-BoNT-A was associated with significantly lower absolute daily disability time compared to Neu-BoNT-A (11.4 vs. 1.2 min/day, < 0.001). No serious adverse events were observed. Both Neu-BoNT-A and Abo-BoNT-A were safe and effective in treating HFS. However, Neu-BoNT-A was more effective in HFS with minimal symptoms without disability and Abo-BoNT-A more effective in HFS with greater duration of disability.
Exploring the Association Between Sleep Patterns, Pubertal Health, and Phthalate Exposure-Preliminary Results from Slovakia
Jahnátková M, Hlisníková H, Petrovičová I and Kolena B
Exploring the Association Between Sleep Patterns, Pubertal Health, and Phthalate Exposure-Preliminary Results from Slovakia
Jahnátková M, Hlisníková H, Petrovičová I and Kolena B
This study aims to explore the association between sleep patterns in children and their exposure to phthalates to assess potential health implications.
How does dental sleep medicine fit into the specialty of orofacial pain?: A narrative review
Moreno-Hay I, Bender S, Alonso A, Lockerman L, Arman S and Mulet Pradera M
How does dental sleep medicine fit into the specialty of orofacial pain?: A narrative review
Moreno-Hay I, Bender S, Alonso A, Lockerman L, Arman S and Mulet Pradera M
Sleep disturbances can lead to an increase in pain and vice versa. Pain, including orofacial pain, can affect sleep quality, leading to poor health, and poor health can affect sleep quality.
Impact of 10 Weeks of Yoga Intervention on Mental Health and Overall Well-Being Among Medical Students: GSY Study
Chauhan S, Najaf SS, Gergely L, Kinga KA, Karsai I and Prémusz V
Impact of 10 Weeks of Yoga Intervention on Mental Health and Overall Well-Being Among Medical Students: GSY Study
Chauhan S, Najaf SS, Gergely L, Kinga KA, Karsai I and Prémusz V
the purpose of this study was to explore the effect of 10 weeks of yoga intervention on the mental health outcomes (stress, anxiety, and depression), quality of life, emotional regulation, and quality of sleep of medical students.
[Pharmacotherapy of obesity in Germany]
Blüher M
[Pharmacotherapy of obesity in Germany]
Blüher M
Pharmacotherapy is part of a comprehensive guideline-conform treatment concept for people with obesity. The foundation of obesity treatment is initially a conservative multimodal basic treatment and consists of a low-energy diet, increased physical activity and behavioral changes. If the individual treatment goals are not achieved with this approach, medications can support the basic treatment. The concept is that drugs should not only achieve weight reduction and stabilization of the reduced body weight but also provide better long-term treatment for the chronic multisystem disease obesity. The incretin-based pharmacotherapy with liraglutide, semaglutide and tirzepatide, which have been introduced in recent years, have not only pronounced weight-reducing but also beneficial cardiometabolic effects. These include improvements in obesity-related comorbidities, such as type 2 diabetes, hypertension, fatty liver disease, obstructive sleep apnea, cardiovascular risk factors, chronic kidney disease and others. In contrast, incretin-based pharmacotherapy is typically associated with mild to moderate gastrointestinal side effects. With the marketing launch of setmelanotide, a medication became available for the treatment of rare monogenic forms of obesity. In addition, numerous incretin-based active agents and new substance classes are in advanced phases of clinical development. Due to their favorable efficacy and side effect profiles and also with respect to the positive cardiometabolic effects, the new drugs have the potential to significantly increase the importance of pharmacotherapy of obesity in Germany.
Sleep problems and insomnia are common and associated with pain intensity, number of comorbidities and analgesic use in patients with knee and hip osteoarthritis: a cross-sectional study using data from the good life with osteoarthritis in Denmark (GLA:D) registry
Thorlund JB, Skarpsno ES, Vestergaard JJ, Skou ST, Grønne DT, Roos EM and Vaegter HB
Sleep problems and insomnia are common and associated with pain intensity, number of comorbidities and analgesic use in patients with knee and hip osteoarthritis: a cross-sectional study using data from the good life with osteoarthritis in Denmark (GLA:D) registry
Thorlund JB, Skarpsno ES, Vestergaard JJ, Skou ST, Grønne DT, Roos EM and Vaegter HB
To assess the difference in prevalence of sleep problems and insomnia in patients with knee or hip osteoarthritis (OA), and explore characteristics associated with sleep problems and insomnia. We included 8,162 knee/hip OA patients enrolled in supervised exercise and patient education through the Good Life with osteoArthritis in Denmark (GLA:D) program. We assessed presence of sleep problems (yes/no), followed by the Insomnia Severity Index 3-item (ISI-3) questionnaire among those with sleep problems (Insomnia: ISI-3 score ≥ 7). Characteristics associated with sleep problems/insomnia was estimated for knee and hip OA patients separately (prevalence ratios [PR]). In total, 68% (n = 3,539) and 64% (n = 1,807) of knee and hip OA patients reported sleep problems, respectively, corresponding to a PR of 1.06 (95% CI 1.03 to 1.10). Prevalence of insomnia was 17% (n = 943) and 20% (n = 528) for those with knee and hip OA, respectively (PR 1.18 [95% CI 1.07 to 1.30]). Large overlap between characteristics associated with sleep problems and insomnia were observed. Characteristics most strongly associated with higher prevalence of insomnia were pain intensity ≥40 mm VAS (knee: PR 2.39 [95% CI 2.08 to 2.74]; hip: PR 2.54 [95% CI 2.10 to 3.07], a high number of comorbidities, and analgesic use in both patients with knee and hip OA. Sleep problems and insomnia are highly prevalent among primary care patients with knee and hip OA, and slightly more common in hip OA patients. Prevalence of insomnia was substantially higher among patients with more comorbidities, higher pain intensity and analgesic use.
Melatonin supplementation: new insights into health and disease
Minari TP and Pisani LP
Melatonin supplementation: new insights into health and disease
Minari TP and Pisani LP
Melatonin supplementation has gained considerable attention for its potential health impacts. This study aimed to review the recent literature on melatonin supplementation and its implications in areas such as obesity, diabetes, gut microbiome, neurodegenerative diseases, cancer, sports performance, sleep quality, psychiatric disorders, pediatrics, pregnancy, and respiratory health. Additionally, assess the supplementation protocols, potential adverse effects, associated risks, and symptoms observed during supplementation.
The effect of breathing exercises on pain, sleep, and symptom management in patients undergoing hemodialysis: a randomized controlled trial
Güvener YÖ and Koç Z
The effect of breathing exercises on pain, sleep, and symptom management in patients undergoing hemodialysis: a randomized controlled trial
Güvener YÖ and Koç Z
This study was conducted to determine the effect of breathing exercises on pain, sleep, and symptom management in patients undergoing hemodialysis.
Impact of Tai Chi Therapy on Fatigue and Cognitive Function in Individuals With Chronic Fatigue Syndrome: Protocol for a Pilot Randomized Controlled Trial
Wang B, Zhang X, Lu P, Sun P and He T
Impact of Tai Chi Therapy on Fatigue and Cognitive Function in Individuals With Chronic Fatigue Syndrome: Protocol for a Pilot Randomized Controlled Trial
Wang B, Zhang X, Lu P, Sun P and He T
Chronic fatigue syndrome (CFS) is a psychosomatic disorder characterized by persistent fatigue, primarily involving physical and mental exhaustion, with greater emphasis on the latter. This leads to a deterioration in concentration and memory. These symptoms affect cognitive functions, including attention and memory, to varying degrees. Previous research has shown that Tai Chi can help reduce fatigue in individuals with CFS. However, the relationship between alleviating CFS-related fatigue through Tai Chi and its impact on cognitive functions remains unclear. The effects of Tai Chi on cognitive functions in individuals with CFS have not been clinically validated, and its efficacy and safety have yet to be examined through large-scale randomized controlled trials. Therefore, this protocol outlines a pilot randomized, parallel, single-blind clinical trial designed to evaluate the impact of Tai Chi therapy on fatigue and cognitive functions in individuals with CFS, using both subjective and objective assessments.
